Construction and immunogenicity study of recombinant MVA vaccine expressing HIV-1 CRF01_AE gp145 gene
10.3760/cma.j.issn.1003-9279.2015.03.023
- VernacularTitle:表达HIV-1CRF01_AE gp145的rMV MVA疫苗构建及免疫原性评价
- Author:
Qianqian ZHAN
1
;
Danying CHEN
;
Jingrong YE
;
Shuangqing YU
;
Ke XU
;
Yi ZENG
;
Xia FENG
Author Information
1. 100124,北京工业大学生命科学与生物医学工程学院病毒与药理室
- Keywords:
AIDS vaccines;
Genes,gp145;
Plasmids;
Poxviridae
- From:
Chinese Journal of Experimental and Clinical Virology
2015;29(3):263-265
- CountryChina
- Language:Chinese
-
Abstract:
Objective To construct recombinant MVA vaccine encoding codon-optimized HIV-1 CRF01_AE gp145 gene and evaluate its immunogenicity in mice.Methods The intracellular region of codon-modified HIV-1 CRF01_AE consensus env gene obtained in our preliminary study was removed to get gp145 gene.The modified gp145 gene was cloned into shuttle plasmid pSC11.BHK-21 cells infected with wild-type MVA in advance were transfected with the recombinant shuttle plasmid.Then the recombinant MVA vaccine expressing gp145 rMVA-AEgp145 was obtained by homologous recombination.After expression of Gp145 was confirmed by WB assay,BALB/c mice were immunized with the recombinant MVA vaccine and the cellular immune responses were evaluated.Results Recombinant MVA vaccine expressed Gp145 protein efficiently and induced high level of cellular immune responses in immunized BALB/c mice.Conclusion The recombinant MVA vaccine encoding HIV-1 CRF01_AE gp145 gene was constructed successfully.This vaccine could induce strong env-specific CTL responses in mice.
